Poster presentation describes the development of SNAP CAR platform technology as a 'universal' CAR therapy with the potential to target multiple antigens through combinatorial use of different adaptors

海报展示描述了SNAP-CAR平台技术作为“通用”CAR疗法的发展，其潜力是通过组合使用不同的衔接子来靶向多种抗原

WEXFORD, Pa., Oct. 31, 2023 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) ('Coeptis' or 'the Company'), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that research demonstrating the potential of the SNAP-CAR T-cell platform to target multiple antigens, including HER2 and CD20, through combinatorial use of different adaptors will be the subject of a poster presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023).

WEXFORD，Pa，2023年10月31日/PRNewswire/-Coeptis Therapeutics Holdings，Inc。（纳斯达克股票代码：COEP）（'Coeptis'或'该公司'），一家开发癌症创新细胞治疗平台的生物制药公司，今天宣布，研究证明SNAP-CAR T细胞平台靶向多种抗原（包括HER2和CD20）的潜力，通过组合使用不同的适配器将成为癌症免疫治疗学会第38届年会（SITC 2023）海报展示的主题。

SITC 2023 is being held Nov. 1–5, 2023, at San Diego Convention Center in San Diego. .

SITC 2023将于2023年11月1日至5日在圣地亚哥的圣地亚哥会议中心举行。 .

The poster presentation titled, 'SNAP CAR T cells for programmable antigen targeting,' describes research involving SNAP-CAR, a 'universal' CAR T cell therapy platform, that demonstrates the technology's versatile antigen targeting abilities both in vitro and in vivo in human tumor xenograft models.

名为“用于可编程抗原靶向的SNAP-CAR T细胞”的海报展示描述了涉及SNAP-CAR的研究，SNAP-CAR是一种“通用”CAR T细胞治疗平台，展示了该技术在体外和体内的多功能抗原靶向能力。人类肿瘤异种移植模型。

In vitro experiments showed potent and specific SNAP-CAR function with co-administered adaptors targeting HER2, EGFR, and CD20 on cancer cell lines including activation of CD69 and CD107a markers, specific target cell lysis, and IFN-gamma production.  Additionally, the researchers tested SNAP-CAR T cells in vivo in a human leukemia tumor xenograft NSG mouse model targeting HER2, observing that SNAP-CAR T cells were able to significantly reduce tumor burden, leading to a lack of detectable tumors in the majority of mice.

体外实验显示有效和特异性SNAP-CAR功能与在癌细胞系上靶向HER2，EGFR和CD20的共同施用的衔接子，包括CD69和CD107a标记物的活化，特异性靶细胞裂解和IFN-γ产生。此外，研究人员在靶向HER2的人白血病肿瘤异种移植NSG小鼠模型中体内测试了SNAP-CAR T细胞，观察到SNAP-CAR T细胞能够显着减轻肿瘤负荷，导致大多数人缺乏可检测的肿瘤。老鼠。

Further, in another leukemia model targeting the CD20 antigen, SNAP-CAR T cells showed significant inhibition of tumor growth. Finally, evaluating two anti-HER2 adaptors with distinct binding epitopes in a human ovarian cancer xenograft model, the researchers observed a significant tumor reduction with both adaptors compared to adaptor only and SNAP-CAR T cell only controls..

此外，在另一种靶向CD20抗原的白血病模型中，SNAP-CAR T细胞显示出对肿瘤生长的显着抑制。最后，在人卵巢癌异种移植模型中评估具有不同结合表位的两种抗HER2衔接子，研究人员观察到与仅衔接子和仅SNAP-CAR T细胞对照相比，两种衔接子均显着减少肿瘤。。

'These findings suggest SNAP-CAR can potentially enable the development of T-cell therapies that can be tuned by adaptor dose and targeted toward multiple antigens through combinatorial use of different adaptors, potentially avoiding toxicities and relapse due to antigen loss,' commented Jason Lohmueller, Ph.D., Assistant Professor of Surgery and Immunology in the Division of Surgical Oncology Research, University of Pittsburgh.

“这些发现表明SNAP-CAR可能有助于开发T细胞疗法，这些疗法可以通过衔接剂量进行调整，并通过组合使用不同的衔接子靶向多种抗原，从而可能避免由于抗原丢失引起的毒性和复发，”Jason Lohmueller博士说。，匹兹堡大学外科肿瘤学研究部外科和免疫学助理教授。

'While still early in its development, we continue to see vast potential for the SNAP-CAR platform for treating both liquid and solid tumor malignancies.'.

“虽然仍处于早期发展阶段，但我们继续看到SNAP-CAR平台治疗液体和实体肿瘤恶性肿瘤的巨大潜力。”。

'The data being presented at SITC 2023 encapsulates the groundbreaking research being conducted at the University of Pittsburgh, which demonstrates the potential of SNAP-CAR T-cells to reduce tumor burden and tumor growth in numerous cancers, including HER2-expressing and CD20-expressing cancers,' said Dave Mehalick, President and CEO of Coeptis Therapeutics.

“SITC 2023提供的数据包含了匹兹堡大学正在进行的开创性研究，该研究证明了SNAP-CAR T细胞在许多癌症中减少肿瘤负荷和肿瘤生长的潜力，包括表达HER2和表达CD20的癌症。'Coeptis Therapeutics总裁兼首席执行官Dave Mehalick说。

'Coeptis is energized more than ever to forge the path forward with the powerful SNAP-CAR platform to develop T-cell and NK-cell technologies for various undertreated cancer indications.'.

“Coeptis比以往任何时候都更有活力，通过强大的SNAP-CAR平台开辟道路，为各种未经治疗的癌症适应症开发T细胞和NK细胞技术。”。

Details of the presentation are as follows:

演示文稿的详细信息如下：

Event:

事件：

Society for Immunotherapy of Cancer's 38th Annual Meeting (SITC 2023)

癌症免疫治疗学会第38届年会（SITC 2023）

Title & Poster #:

标题和海报＃：

SNAP CAR T cells for programmable antigen targeting, Poster #299

用于可编程抗原靶向的SNAP CAR T细胞，海报＃299

Date & Time:

日期和时间：

November 3, 2023 (5:10–6:40 p.m.)

2023年11月3日（下午5:10-6:40）

Presenter:

节目主持人：

Dr. Elisa Ruffo, Postdoctoral Researcher, University of Pittsburgh

匹兹堡大学博士后研究员Elisa Ruffo博士

About Coeptis Therapeutics Holdings, Inc.

关于Coeptis Therapeutics Holdings，Inc。

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively 'Coeptis'), is a biopharmaceutical company developing innovative cell therapy platforms for cancer that have the potential to disrupt conventional treatment paradigms and improve patient outcomes.

Coeptis Therapeutics Holdings，Inc.及其子公司，包括Coeptis Therapeutics，Inc。和Coeptis Pharmaceuticals，Inc。（统称为Coeptis'），是一家开发创新癌症细胞治疗平台的生物制药公司，有可能破坏传统治疗范式并改善患者预后。

Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR™ cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet.

Coeptis的产品组合和权利由Deverra Therapeutics许可的资产突出显示，包括同种异体细胞免疫治疗平台和DVX201，临床阶段，未经修改的自然杀伤细胞治疗技术。此外，Coeptis正在开发一种通用的多抗原CAR T技术，该技术获得匹兹堡大学（SNAP-CAR）和装备的许可™ 细胞疗法和伴随诊断平台，Coeptis正在与VyGen Bio和Karolinska Institutet的领先医学研究人员合作开发。

Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer.

Coeptis的商业模式旨在通过许可协议，许可协议和共同开发关系最大化其当前产品组合和权利的价值，并签订战略合作伙伴关系以扩展其产品权利和产品，特别是针对癌症的产品权利和产品。

The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com/..

该公司总部设在宾夕法尼亚州韦克斯福德，了解有关Coeptis访问的更多信息https://coeptistx.com/..

About the Emerging Growth ConferenceThe Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.  The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth.

关于新兴增长会议新兴增长会议是公共公司在办公室方便的情况下，以省时的方式向投资界展示和传达其新产品，服务和其他重大公告的有效方式。会议重点和覆盖范围包括广泛增长部门的公司，拥有强大的管理团队，创新的产品和服务，重点战略，执行和长期增长的整体潜力。

Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.  All sessions will be conducted through video webcasts and will take place in the Eastern time zone..

其受众包括成千上万的个人和机构投资者，以及投资顾问和分析师。所有会议将通过视频网络广播进行，并将在东部时区举行。。

Cautionary Note Regarding Forward-Looking Statements This press release and statements of our management made in connection therewith contain or may contain 'forward-looking statements' (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended).

关于前瞻性陈述的警示 本新闻稿和我们与之相关的管理层声明包含或可能包含“前瞻性声明”（如1933年“证券法”第27A条（经修订）和1934年“证券交易所法”第21E条所定义，作为修订）。

Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as 'may,' 'will,' 'intend,' 'should,' 'believe,' 'expect,' 'anticipate,' 'project,' 'estimate' or similar expressions that do not relate solely to historical matters, we are making forward-looking statements.

前瞻性陈述包括关于我们的计划，目标，目标，策略，未来事件或表现以及基本假设的陈述，以及除历史事实陈述之外的其他陈述。当我们使用诸如“可能”，“将会”，“意图”，“应该”，“相信”，“期望”，“预期”，“项目”，“估计”或类似的表达方式时，我们正在做出前瞻性的陈述。

Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S.

前瞻性陈述不能保证未来的业绩，并且涉及重大风险和不确定性，可能导致实际结果与我们在前瞻性陈述中讨论的预期大不相同，甚至可能大不相同。可能导致这种差异的因素包括但不限于：（1）无法在纳斯达克资本市场维持本公司证券的上市；（2） Deverra许可资产整合将破坏公司当前计划和运营的风险；（3） 无法承认新许可资产的预期收益，这可能受到竞争，公司经济增长和管理增长以及雇用和留住关键员工的能力等因素的影响；（4） 公司正在开发的产品或新许可资产未通过临床试验或未经美国批准的风险。

Food and Drug Administration or other applicable regulatory authorit.

食品药品监督管理局或其他适用的监管机构。

CONTACTS

联络

Coeptis Therapeutics, Inc.Andy Galy, Sr. VP of Communications[email protected]

Coeptis Therapeutics，Inc.Andy Galy，Sr。通信副总裁[电子邮件保护]

Tiberend Strategic Advisors, Inc.InvestorsDaniel Kontoh-Boateng[email protected]

Tiberend Strategic Advisors，Inc.InvestorsDaniel Kontoh Boateng[电子邮件保护]

MediaDavid Schemelia[email protected]

MediaDavid Schemelia[电子邮件保护]

SOURCE Coeptis Therapeutics

来源Coeptis Therapeutics